Dr. Tyrone C. Malloy: Family Planning

                                                   Randomized Oral V. Vaginal                                    

                                                Misoprostol at 24 Hours After

                                                Mifepristone for Abortion up to

                                                63 Days Gestation.

                                                Principal Investigator                                                             

                                                Role of Routine Ultrasound with                                                                 Mifepristone and Vaginal Misoprostol

                                                for Abortion up to 63 Days Gestation.

                                                Principal Investigator

Constipation                          A Double-Blind, Randomized, Placebo-Controlled, Parallel Group,  Multi-Site Study to Evaluate the Clinical Equivalence of XXXX with XXXX in the Treatment of Chronic Idiopathic Constipation

                                                Principal Investigator

                                                Sponsor: Anchen Pharmaceuticals, Inc.

Urology-

Urinary Incontinence            A Multicenter, Randomized, Double-Blind, Parallel group Study to Evaluate the Efficacy and Safety of Two Doses of X vs. Placebo in Women with Overactive Bladder

                     Principal Investigator            

Sponsor: Duramed Research, Inc.

A Placebo Controlled Randomized, 12 Week, Dosing-Ranging, Double Blind Study vs. Placebo using Tolterodine as a Study Calibrator, to evaluate Efficacy and Safety of XX in women with Overactive Bladder Including Urge Urinary Incontinence

Principal Investigator

Sponsor: Sanofi-Aventis                    

A Multicenter, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of X Versus Placebo in Women Diagnosed With Overactive Bladder Who Have Symptoms of Predominant or Pure Urge Incontinence, Urgency and Frequency

                                                Principal Investigator

                                                Sponsor: Duramed Research, Inc.